Emerging treatments for rheumatoid arthritis: Update

Christine Savage, E. William St. Clair, John S. Sundy

Research output: Contribution to journalShort survey

Abstract

Early treatment with disease-modifying anti-rheumatic drugs (DMARDs)-alone or in combination-can prevent joint damage and minimize disability. Until recently, the DMARDs used predominantly in patients with rheumatoid arthritis had been methotrexate, sulfasalazine, and hydoxychloroquine. Older DMARDs such as gold, D-penicillamine, and azathioprine have fallen out of favor because of their long-term toxicities or modest benefit. Six newer DMARDs-leflunomide, etanercept, infliximab, adalimumab, rituximab, and anakinra-have greatly expanded the current treatment options.

Original languageEnglish (US)
Pages (from-to)984-995
Number of pages12
JournalConsultant
Volume45
Issue number9
StatePublished - Aug 1 2005

Keywords

  • Disease-modifying anti-rheumatic drugs
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Emerging treatments for rheumatoid arthritis: Update'. Together they form a unique fingerprint.

  • Cite this

    Savage, C., St. Clair, E. W., & Sundy, J. S. (2005). Emerging treatments for rheumatoid arthritis: Update. Consultant, 45(9), 984-995.